Jubilant commits CAD 94.5 million to double RUBY-FILL capacity; Canada funds a quarter of it
Jubilant Draximage will expand its Kirkland, Québec plant with CAD 23.8 million of Canadian government support. The stock closed −0.5% in the first session after the filing.
₹930.00
Oct 9 close, −0.5% on the day
≈ ₹14,813 Cr
15.93 Cr shares × last close
MID-CAP
by market cap ≈ ₹14,813 Cr
CAD 94.5 million
Kirkland, Québec facility
CAD 23.8 million
Canada's Strategic Response Fund
−21.5%
adjusted high ₹1,184.8 (Oct 21, 2025)
A capacity-doubling investment in the flagship radiopharma product
Jubilant Radiopharma announces CAD 94.5 million to double RUBY-FILL production capacity
Jubilant Draximage Inc. — a subsidiary of Jubilant Pharma Limited, the company's wholly owned subsidiary — announced an investment of CAD 94.5 million to modernise and expand its Kirkland, Québec facility and increase production capacity across its radiopharmaceutical portfolio. The investment is specifically aimed at doubling production capacity of the flagship product RUBY-FILL®. The Government of Canada will provide financial support of CAD 23.8 million through the Strategic Response Fund's innovation funding stream. The release states the business continues to see very strong demand for RUBY-FILL and that its customer base has doubled in the last three years. The filing reached the exchange at 21:23 IST on Thursday, October 8 — after market close.
Read:RUBY-FILL enables on-site production of Rubidium-82 for cardiac PET imaging, and the Kirkland facility is, per the release, the only site in Canada producing these product categories. A capacity doubling framed as a response to elevated demand — with roughly a quarter of the outlay co-funded by the Canadian government — is a capex commitment to the Radiopharma business, one of the company's six listed business lines.
BSE filing + press release, Oct 8, 2026The mechanics, as the filing states them: the investing entity is Jubilant Draximage Inc., sitting under Jubilant Pharma Limited, Singapore, which is wholly owned by listed Jubilant Pharmova. The money goes into modernising and expanding the Kirkland site — including installation of production equipment — to double manufacturing capacity for RUBY-FILL. Canada's contribution of CAD 23.8 million works out to about 25% of the CAD 94.5 million total. Harsher Singh, CEO of the Jubilant Radiopharma business, said the project will "build our deep capability here in Quebec, create and secure high-value jobs, and ensure a reliable supply of essential radiopharmaceutical products in Canada and around the world."
What the filing does not contain is as relevant: no completion timeline, no phasing, and no revenue or margin guidance for the expanded capacity. The demand claim is specific — the customer base has doubled in three years — but unquantified in revenue terms. This reads as a demand-led capacity bet on a product the company itself calls its flagship; whether it moves consolidated numbers, and when, is not something the filing establishes.
A growing top line, a compressed margin, and a fundraising board meeting
The capex lands against a mixed Q1 FY27. Per the company's August 10 results release: revenue of ₹2,229 crore grew 17% year-on-year with growth across all business segments, but EBITDA fell 11% to ₹268 crore, EBITDA margin compressed 385 bps to 11.9%, and reported PAT dropped 45% to ₹56 crore. The company framed the quarter as "on track towards Vision 2030". Promoter holding was unchanged at 47.68% between March and June 2026.
Consolidated figures from exchange filings. Q1 FY27 operating margin of 11.1% compares with 15.2% a year earlier.
The pattern across five quarters: revenue has climbed from ₹1,901 crore to ₹2,229 crore, while profitability has alternated — operating margin peaked at 17.1% in Q2 FY26 and sits at 11.1% in the latest quarter. Funding a CAD 94.5 million capex from this P&L is the question the next filing in the sequence raises: on October 7, a day before the Kirkland announcement, the company called a board meeting for Monday, October 12 to consider raising funds through non-convertible debentures and to approve seeking shareholders' approval as may be required. Neither filing links the NCDs to the Kirkland project — any connection is inference until the board outcome says otherwise.
USFDA approves commercial batch manufacturing of the first product on Line 3, the new isolator-based fill-and-finish line at the Spokane, USA contract-manufacturing facility. First traded Aug 24: +2.5%.
USFDA concludes its review of the Establishment Inspection Report for the Spokane facility with a 'Voluntary Action Indicated' determination.
Board meeting called for Oct 12 to consider raising funds through NCDs and/or other permitted securities.
CAD 94.5 million Kirkland investment announced to double RUBY-FILL capacity; Government of Canada contributing CAD 23.8 million.
Taken together, the last seven weeks of filings describe a company putting capital and regulatory milestones into its North American manufacturing footprint — Spokane on the CDMO side, Kirkland on radiopharma — while the fundraising question heads to the board. That is the sequence the filings support; the sizing and timing of each piece remain undisclosed.
A muted first-session reaction at the end of a two-week slide
The reaction was muted: the filing hit the exchange at 21:23 IST on October 8, and the first session it could trade — October 9 — closed at ₹930.00, down 0.5% on light volume (1.2 lakh shares against 4.2 lakh the prior day). The bigger moves of the window came elsewhere: the stock fell 7.7% on August 12, the second session after Q1 results; rallied 18.1% from ₹907.60 on September 1 to ₹1,071.95 on September 25 — a rise the filings in this window do not account for — and has since given back 13.2% to ₹930. At that close the stock sits 21.5% below its adjusted 52-week high of ₹1,184.8 and 18.3% above the March low of ₹786.05.
The filings that would change the picture
Oct 12 board outcome
The NCD fundraising decision — size, tenor and stated purpose would show whether the raise connects to the Kirkland capex or to something else entirely.
Q2 FY27 results
The trading window closed October 1 and stays closed until 48 hours after the September-quarter results. Whether EBITDA margin recovers from Q1's 11.9% is the open question the capex sits on top of.
Kirkland specifics
The press release gives no completion timeline, phasing or revenue guidance for the expansion. Subsequent filings or the next results presentation may fill those in.
Spokane follow-through
With Line 3 USFDA-approved and the facility's inspection closed at 'Voluntary Action Indicated', CDMO commentary in the next results release would show whether the capacity is converting.
What the filing establishes is narrow but concrete: a CAD 94.5 million commitment to double capacity for a product the company calls its flagship, at the only Canadian site producing these categories, with the Government of Canada funding about a quarter of it through the Strategic Response Fund — and a stated demand backdrop of a customer base that has doubled in three years.
What it does not establish is the financial shape of the bet — cost phasing, timeline, or the revenue the doubled capacity is expected to carry — and it arrives in a quarter where operating margin compressed 385 bps. The near-flat first-session reaction suggests the market is waiting for those specifics, with the October 12 board meeting the first scheduled chance to get some.
Informational and educational content only. Not investment advice.